ArticleMolecular medicine reports2026
Construction and validation of a nomogram for the diagnosis of postmenopausal osteoporosis.
Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoporosis (OP) is an increasing global public health concern and practical tools for predicting and detecting postmenopausal osteoporosis (PMOP) at an early stage are still needed. The present study aimed to develop and validate an individualized diagnostic prediction model for PMOP to facilitate risk assessment and guide therapeutic strategies for high‑risk patients. RNA sequencing data and corresponding clinical features were obtained from the Gene Expression Omnibus database (training group, n=90) and The Fourth Affiliated Hospital of School of Medicine and International School of Medicine, Zhejiang University, Zhejiang China (validation group, n=18). Gene Set Enrichment Analysis (GSEA) and Protein‑Protein Interaction (PPI) network analyses were used to identify hub genes associated with OP. Univariate, multivariate, least absolute shrinkage and selection operator logistic regression analyses were performed to identify the factors and generate a dynamic nomogram. Validation was performed using the receiver operating characteristic curve and decision curve analysis (DCA) to evaluate the effectiveness and net benefit of the clinical prediction nomogram. PPI and GSEA identified 13 estrogen‑response‑related hub genes (CD44, FDFT1, SLC29A1, P2RY2, RHOBTB3, TNNC1, RPS6KA2, TSKU, CYP26B1, SEMA3B, SYT12, IL17RB and ELF3) that were incorporated into a risk score model. A nomogram combining this risk score with clinical parameters demonstrated a promising preliminary diagnostic performance for OP. DCA indicated that the combined risk score and clinical‑factor model provided the highest net benefit. The clinical prediction nomogram exhibited a promising preliminary performance in both the training and validation groups. The present study developed a novel diagnostic nomogram for predicting PMOP. This exploratory tool showed potential clinical utility for risk stratification, although prospective validation in larger cohorts is required before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.